Cargando…
Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV
After solid-organ transplantation, reactivation of the cytomegalovirus (CMV) is often observed in seronegative patients and associated with a high risk of disease and mortality. CMV-specific T cells can prevent CMV reactivation. In a phase 1 trial, CMV-seronegative patients with end-stage renal dise...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835207/ https://www.ncbi.nlm.nih.gov/pubmed/35162953 http://dx.doi.org/10.3390/ijms23031029 |
_version_ | 1784649372652273664 |
---|---|
author | Bunse, Lukas Sommerer, Claudia Tan, Chin Leng Korell, Felix Schmitt, Anita Hückelhoven-Krauss, Angela Neuber, Brigitte Mertens, Thomas Platten, Michael Green, Edward W. Zeier, Martin Schmitt, Michael |
author_facet | Bunse, Lukas Sommerer, Claudia Tan, Chin Leng Korell, Felix Schmitt, Anita Hückelhoven-Krauss, Angela Neuber, Brigitte Mertens, Thomas Platten, Michael Green, Edward W. Zeier, Martin Schmitt, Michael |
author_sort | Bunse, Lukas |
collection | PubMed |
description | After solid-organ transplantation, reactivation of the cytomegalovirus (CMV) is often observed in seronegative patients and associated with a high risk of disease and mortality. CMV-specific T cells can prevent CMV reactivation. In a phase 1 trial, CMV-seronegative patients with end-stage renal disease listed for kidney transplantation were subjected to CMV phosphoprotein 65 (CMVpp65) peptide vaccination and further investigated for T-cell responses. To this end, CMV-specific CD8(+) T cells were characterized by bulk T-cell-receptor (TCR) repertoire sequencing and combined single-cell RNA and TCR sequencing. In patients mounting an immune response to the vaccine, a common SYE(N)E TCR motif known to bind CMVpp65 was detected. CMV-peptide-vaccination-responder patients had TCR features distinct from those of non-responders. In a non-responder patient, a monoclonal inflammatory T-cell response was detected upon CMV reactivation. The identification of vaccine-induced CMV-reactive TCRs motifs might facilitate the development of cellular therapies for patients wait-listed for kidney transplantation. |
format | Online Article Text |
id | pubmed-8835207 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88352072022-02-12 Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV Bunse, Lukas Sommerer, Claudia Tan, Chin Leng Korell, Felix Schmitt, Anita Hückelhoven-Krauss, Angela Neuber, Brigitte Mertens, Thomas Platten, Michael Green, Edward W. Zeier, Martin Schmitt, Michael Int J Mol Sci Article After solid-organ transplantation, reactivation of the cytomegalovirus (CMV) is often observed in seronegative patients and associated with a high risk of disease and mortality. CMV-specific T cells can prevent CMV reactivation. In a phase 1 trial, CMV-seronegative patients with end-stage renal disease listed for kidney transplantation were subjected to CMV phosphoprotein 65 (CMVpp65) peptide vaccination and further investigated for T-cell responses. To this end, CMV-specific CD8(+) T cells were characterized by bulk T-cell-receptor (TCR) repertoire sequencing and combined single-cell RNA and TCR sequencing. In patients mounting an immune response to the vaccine, a common SYE(N)E TCR motif known to bind CMVpp65 was detected. CMV-peptide-vaccination-responder patients had TCR features distinct from those of non-responders. In a non-responder patient, a monoclonal inflammatory T-cell response was detected upon CMV reactivation. The identification of vaccine-induced CMV-reactive TCRs motifs might facilitate the development of cellular therapies for patients wait-listed for kidney transplantation. MDPI 2022-01-18 /pmc/articles/PMC8835207/ /pubmed/35162953 http://dx.doi.org/10.3390/ijms23031029 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bunse, Lukas Sommerer, Claudia Tan, Chin Leng Korell, Felix Schmitt, Anita Hückelhoven-Krauss, Angela Neuber, Brigitte Mertens, Thomas Platten, Michael Green, Edward W. Zeier, Martin Schmitt, Michael Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV |
title | Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV |
title_full | Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV |
title_fullStr | Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV |
title_full_unstemmed | Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV |
title_short | Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV |
title_sort | common t-cell-receptor motifs and features in patients with cytomegalovirus (cmv)-seronegative end-stage renal disease receiving a peptide vaccination against cmv |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835207/ https://www.ncbi.nlm.nih.gov/pubmed/35162953 http://dx.doi.org/10.3390/ijms23031029 |
work_keys_str_mv | AT bunselukas commontcellreceptormotifsandfeaturesinpatientswithcytomegaloviruscmvseronegativeendstagerenaldiseasereceivingapeptidevaccinationagainstcmv AT sommererclaudia commontcellreceptormotifsandfeaturesinpatientswithcytomegaloviruscmvseronegativeendstagerenaldiseasereceivingapeptidevaccinationagainstcmv AT tanchinleng commontcellreceptormotifsandfeaturesinpatientswithcytomegaloviruscmvseronegativeendstagerenaldiseasereceivingapeptidevaccinationagainstcmv AT korellfelix commontcellreceptormotifsandfeaturesinpatientswithcytomegaloviruscmvseronegativeendstagerenaldiseasereceivingapeptidevaccinationagainstcmv AT schmittanita commontcellreceptormotifsandfeaturesinpatientswithcytomegaloviruscmvseronegativeendstagerenaldiseasereceivingapeptidevaccinationagainstcmv AT huckelhovenkraussangela commontcellreceptormotifsandfeaturesinpatientswithcytomegaloviruscmvseronegativeendstagerenaldiseasereceivingapeptidevaccinationagainstcmv AT neuberbrigitte commontcellreceptormotifsandfeaturesinpatientswithcytomegaloviruscmvseronegativeendstagerenaldiseasereceivingapeptidevaccinationagainstcmv AT mertensthomas commontcellreceptormotifsandfeaturesinpatientswithcytomegaloviruscmvseronegativeendstagerenaldiseasereceivingapeptidevaccinationagainstcmv AT plattenmichael commontcellreceptormotifsandfeaturesinpatientswithcytomegaloviruscmvseronegativeendstagerenaldiseasereceivingapeptidevaccinationagainstcmv AT greenedwardw commontcellreceptormotifsandfeaturesinpatientswithcytomegaloviruscmvseronegativeendstagerenaldiseasereceivingapeptidevaccinationagainstcmv AT zeiermartin commontcellreceptormotifsandfeaturesinpatientswithcytomegaloviruscmvseronegativeendstagerenaldiseasereceivingapeptidevaccinationagainstcmv AT schmittmichael commontcellreceptormotifsandfeaturesinpatientswithcytomegaloviruscmvseronegativeendstagerenaldiseasereceivingapeptidevaccinationagainstcmv |